Table 2.

Targeting the polyamine-hypusine pathway

Cancer type	Target	Drug/agent	Combination therapy	Cell line	Inhibitory effect	References
Ex vivo
Leukemia	DHPS	GC7	Imatinib	BCR-ABL+	Synergistic effect	Balabanov et al. (2007)
Glioblastoma	DHPS	GC7	Temozolomide (TMZ), Bischloroethyl-nitrosourea (BCNU)	U87-MG, G55T2	Additive effect	Preukschas et al. (2012)
Lung (NSCLC)	DHPS	GC7	Cisplatin	H1299, A549	Increased sensitivity to cisplatin	Xu et al. (2014)
Lung (NSCLC)	eIF5A	siRNA	Cisplatin	H1299, A549	Increased sensitivity to cisplatin	Xu et al. (2014)
Prostate cancer	DOHH	miRNA	Mimosine	DU145	Synergistic effect	Epis et al. (2012)
Cancer type/other disease	Target	Drug/agent	Combination therapy	Mouse models	Inhibitory effect	References
In vivo
B-cell cancers (MM, MCL, and DLBCL)	eIF5A	SNS01	–	Xenograft of B-cell cancers	Inhibited tumor growth	Francis et al. (2014)
			Lenalidmide	Xenograft of B-cell cancers	Synergistic effect	Francis et al. (2014)
			Bortezomib	Xenograft of B-cell cancers	Synergistic effect	Francis et al. (2014)
Islet beta cell inflammation/diabetes	DHPS	GC7	–	Low-dose streptozotocin (STZ) model	Reduced inflammatory response	Maier et al. (2010)
Type 1 diabetes (T1D)	DHPS	GC7	–	Humanized mouse model of T1D	Does not abrogate the development of T1D	Imam et al. (2014)
Severe sepsis	eIF5A	siRNA-liposome complexes	–	Mouse model of severe sepsis	Reduced inflammation and increased survival	Moore et al. (2008)

MM multiple myeloma, MCL mantle cell lymphoma, DLBCL diffuse large B-cell lymphoma